Emcure Pharmaceuticals has released its investor presentation for June 2026, detailing strong performance across various segments. The company reported USD 1 Bn+ in TTM Revenue from Operations, with a domestic contribution of ~44%. Key highlights include robust revenue growth, margin expansion driven by operating leverage, and a strong R&D pipeline. Strategic in-licensing and acquisitions are further augmenting its business, particularly in domestic and international markets.
Emcure at a Glance
Emcure Pharmaceuticals presented a robust financial overview for the period ending June 2026. The company achieved USD 1 Bn+ in TTM Revenue from Operations, with domestic contribution standing at ~44%. It also boasts 11/32 brand families with revenue exceeding INR 100/50Cr, and 19 of its top 20 brands ranking in the top 3 across respective therapeutic areas (TAs). Domestically, Emcure holds the #2 rank in Gynecology and is the largest player in its covered markets, with a ~50% revenue share from complex products. Internationally, the company operates in 70+ countries, with a ~30% revenue share from complex products and significant revenue share from Europe/Canada/RoW (20%/16%/20%), having launched over 900+ products.
Key Deliverables Since IPO
Since its IPO, Emcure has successfully delivered on several fronts:
- Achieved faster than industry growth across markets.
- Experienced margin expansion driven by operating leverage.
- Developed a robust in-house R&D pipeline across key platforms.
- Completed several accretive M&A / strategic in-licensing deals.
- Augmented its domestic franchise with experienced leadership and products.
- Scaled up its international business with differentiated products.
Financial Performance FY26 Snapshot
The company reported strong revenue growth of 16.6% in FY26, reaching INR 9,204 Cr. EBITDA and Adj PAT margins also saw significant improvements, standing at 19.4% and 10.9% respectively. Key highlights for FY26 include revenue growth above guidance, driven by strong performance in international markets. The domestic business grew in line with IPM, boosted by Cardiac, CNS, and oncology segments. EBITDA margins improved by 80 bps to 19.4%, attributed to productivity enhancement and scaling of in-house products, while Adj. PAT margin improved by 189 bps to 10.9%. ROCE improved by 180 bps to 23.8%.
Operating Leverage Linked Margin Expansion
Emcure has demonstrated consistent margin expansion linked to operating leverage. EBITDA grew from INR 1,230 Cr in FY24 to INR 1,789 Cr in FY26, with margins increasing from 18.5% to 19.4%. PAT grew from INR 528 Cr to INR 941 Cr, with margins expanding from 7.9% to 10.2%. This expansion was driven by improved productivity, better utilization, and stringent cost control.
Strong Global Pipeline of Differentiated Products
Emcure is focused on building a strong global pipeline, positioning platforms to drive near- and long-term growth. The pipeline includes key products across various therapeutic areas such as Anti-Diabetes (Semaglutide), Ophthalmology (Bevacizumab), Oncology (Oncology Biosimilar, ADC, LAI), and Anti-Infectives (Liposomal Amphotericin B). The company is also developing NDDS, Complex Inj, LAI, and ADC products for medium-to-long term growth.
Augmented by Strategic In-Licensing & Acquisitions
Emcure has strategically augmented its portfolio through in-licensing partnerships and acquisitions. Key in-licensing deals include agreements with Sanofi for oral anti-diabetic products, Novo Nordisk for exclusive rights to Poviztra (semaglutide injection) for weight loss, and Roche for nephrology and transplant brands. Strategic acquisitions include full control of Zuventus Healthcare and the asset purchase of Manx Healthcare by its UK subsidiary.
India Business Performance FY26
The domestic business showed strong performance, with revenue growing to INR 4,027 Cr in FY26, a +10.0% YoY growth. Growth was in line with IPM, supported by productivity enhancements and new leadership hires. Portfolio expansion through partnerships with Novo Nordisk, Sanofi, and Roche is also contributing significantly. The key takeaway is that the domestic business is poised for its next leap, backed by stronger leadership and an enhanced portfolio.
India – Augmented with New Areas, In-Licensing & Leadership
Emcure’s India operations are augmented by expansion into new areas, in-licensing, and strong leadership. The company has seen PPM growth of +23%, with the number of large brands growing 4X from FY20 to FY26, reaching 32. Chronic share also saw an uptake of 12% to 38.3% in FY26. The company has a specialized experienced leadership team and key verticals including In-house Product Pipeline, In-Licensing, New Growth Areas, and Strategic Execution.
India Portfolio Map – Leadership in Key TAs
Emcure holds leadership positions in key therapeutic areas within its India portfolio. The company has 25+ years of experience and focuses on Women Health & Cardio-Diabeto, which account for 50% of India sales. Zuventus, now a 100% subsidiary, brings its own expertise. The portfolio includes anchor brands in Gynecology, Cardiovascular, Diabetology, HIV, and Zuventus-specific therapy areas like Nutrition and Anti-infective.
India – Expansion into New Therapeutic Segments
Emcure is expanding its presence into new therapeutic segments in India, including Super Specialty, Consumer (OTC), and Dermatology. In Super Specialty, it is led by experienced leaders with a focus on Renal, Oncology, and CNS, with a new pipeline in Ophthalmology and Oncology. The Consumer (OTC) segment targets a USD 12 Bn market with lines like Arth wellness and Galact pregnancy support. The Dermatology segment targets a USD 1.8+ Bn industry with prescription and cosmo-derma products.
Europe – Strong Injectable Portfolio to Drive Growth
Europe presents a USD 70 Bn+ generics market opportunity, with Emcure growing at a faster pace of +11.4% CAGR, reaching INR 1,850 Cr in FY26. Key growth drivers include the base business, Liposomal Amphotericin B, and the Manx portfolio. Emcure is the first company to launch generic Amphotericin B in a ~USD 270 Mn innovator sales market. The EU pipeline has over 55+ products under development, and complex injectables are expected to drive the next leg of growth, targeting a TAM of USD 1 Bn+.
Canada – Leadership Position with a Long Growth Runway
Canada’s generic market is growing at ~8% (CAD Bn), and Emcure is growing faster than the industry at +26.8% CAGR, reaching INR 1,487 Cr in FY26. Emcure is among the top 10 generic players and the largest Indian Company by prescription in Canada. It has a strong product pipeline of 50+ products (TAM: ~CAD 3 Bn) and is the first generic for 8 near-term products in the pipeline. Key pipeline products include Amantadine, Sulfamethoxazole/Trimethoprim, and Semaglutide inj.
RoW – At an Inflection Point
The Rest of the World (RoW) market is at an inflection point, with strong growth over the past few years at +20.9% CAGR, reaching INR 1,840 Cr in FY26. The business includes a mix of ARV and Non-ARV segments, with the Non-ARV business showing strong growth driven by key product launches, including complex injectables and biosimilars. The TAM for this segment is USD 2 Bn+. The healthy pipeline of differentiated products includes Amphotericin B, Tenecteplase, Lenacapavir, Ferric Carboxymaltose, Bevacizumab, and Enoxaparin.
Key Takeaways
Emcure’s strategy is built on three pillars: Consistent Compounding, achieving low-to-mid teens revenue growth with margin expansion; Balanced Diversification, ensuring balanced growth across India and global markets; and a Future-ready Pipeline, featuring complex products to sustain long-term growth.
P&L Summary | Q4 & Full Year FY26
For Q4 FY26, Revenue from Operations stood at INR 2,470 Cr, a 16.7% YoY increase. Full-year FY26 Revenue from Operations reached INR 9,204 Cr, up 16.6% YoY. Gross Profit Margin was 60.3% in FY26, and EBITDA Margin was 19.4%. Profit Before Tax (PBT) for FY26 was INR 1,287 Cr, with Profit After Tax (PAT) at INR 941 Cr. Adj PAT for FY26 was INR 1,008 Cr, showing a 40.9% YoY growth. Adj. PAT Margin improved significantly to 10.9%.
Balance Sheet Summary
As of March 31, 2026, Emcure’s Shareholder Funds were INR 4,950 Cr. Total Liabilities stood at INR 9,376 Cr, with Borrowings at INR 1,204 Cr. Total Assets also amounted to INR 9,376 Cr, with Fixed Assets at INR 3,592 Cr and Current Assets at INR 5,527 Cr. The Net Debt as of March 31, 2026, was INR 1,054 Cr.
Cash Flow Statement | Full Year FY26
For the full year FY26, Net cash from operations was INR 944 Cr. Net Cash used for Investment was (INR 1,193 Cr), primarily due to Capex and acquisitions. Net Cash from Financing was INR 343 Cr, reflecting an increase in debt and fresh issuance of shares.
Source: BSE
